Amanda Thuringer
Neurology · Kansas City, KSNPI 1124446406
Payments from drug & device makers
What this record shows
This record is dominated by grants: $85,775 of the $86,920 with a category attached, or 98.7%. Biogen accounts for 98.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $85,775 and has fallen 99.7% since, to $235 in 2025. Among neurology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $1379.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$86K
- Bristol Myers Squibb$395
- Amgen$212
- Vanda Pharmaceuticals Inc.$95
- Hospira, Inc.$93
- EMD Serono, Inc.$79
- plus $257 from 9 others
What the payments were for
- Grants$85,77599%
- Food & beverage$1,0641%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 2 | $85,788 |
| Bristol Myers Squibb | 24 | $395 |
| Amgen(2 entities) | 11 | $212 |
| Vanda Pharmaceuticals Inc. | 3 | $95 |
| Hospira, Inc. | 6 | $93 |
| EMD Serono, Inc. | 3 | $79 |
| Sanofi | 2 | $44 |
| Cycle Pharmaceuticals Inc | 2 | $42 |
| AbbVie | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| TG Therapeutics, Inc. | 1 | $29 |
| Novartis | 2 | $27 |
| Banner Life Sciences, LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Pfizer | 1 | $14 |
How this compares
$86,920 in reported general payments places this provider in the 90th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 111 | $1,019,456 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 75 | $548,611 |
| ZeposiaOzanimod Hydrochloride | 30 | $326,304 |
| VumerityDiroximel Fumarate | 38 | $302,498 |
| TecfideraDimethyl Fumarate | 33 | $292,736 |
| EnspryngSatralizumab-Mwge | 18 | $276,646 |
| MayzentSiponimod | 29 | $262,410 |
| Glatiramer Acetate | 74 | $166,882 |
| AubagioTeriflunomide | 16 | $164,691 |
| TysabriNatalizumab | 18 | $148,012 |
| Humira(Cf) PenAdalimumab | 15 | $101,244 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $100,927 |
| CopaxoneGlatiramer Acetate | 18 | $98,983 |
| Dalfampridine ErDalfampridine | 240 | $43,541 |
| Dimethyl Fumarate | 59 | $42,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Tecfidera, Tysabri, Avonex (4 Pack) | $85,788 | $844,174102 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $30 | $326,30430 claims |
| NovartisMayzent | $27 | $262,41029 claims |
| SanofiAubagio | $44 | $164,69116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 131 neurology providers in Kansas.
Other neurology in Kansas City
- Ivan OsorioKansas City$101.7M
- Rajesh PahwaKansas City$889K
- Richard DubinskyKansas City$122K
- Jeffrey BurnsKansas City$115K
- Mamatha PasnoorKansas City$86K
- Michael AbrahamKansas City$48K
- Constantine FarmakidisKansas City$25K
- Andrew CreedKansas City$16K
- James AppelbaumKansas City$15K
- Patrick LandazuriKansas City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.